A polygenic risk score added to a QRISK®2 cardiovascular disease risk calculator demonstrated robust clinical acceptance and clinical utility in the primary care setting

Author:

Fuat Ahmet1,Adlen Ella2,Monane Mark2,Coll Ruth2,Groves Sarah2,Little Elizabeth3,Wild Jonathan4,Kamali Farzan J5,Soni Yusuf6,Haining Shona7,Riding Helen7,Riveros-Mckay Fernando2,Peneva Iliana2,Lachapelle Alexander2,Giner-Delgado Carla2,Weale Michael E2,Plagnol Vincent2,Harrison Seamus2ORCID,Donnelly Peter2

Affiliation:

1. Durham University , Durham , UK

2. Genomics plc , King Charles House, Park End Street, Oxford OX1 1JD , UK

3. Wellspring Medical Practice , Newcastle upon Tyne , UK

4. Pelton and Fellrose Medical Group , Pelton , UK

5. Hadrian Primary Care Alliance , Stocksfield , UK

6. Riverside General Practice , Stockton-on-Tees , UK

7. Research and Evidence, NHS North of England Commissioning Support , Durham , UK

Abstract

Abstract Aims The aim of the study was to assess the real-world feasibility, acceptability, and impact of an integrated risk tool for cardiovascular disease (CVD IRT, combining the standard QRISK®2 risk algorithm with a polygenic risk score), implemented within routine primary practice in the UK National Health Service. Methods and results The Healthcare Evaluation of Absolute Risk Testing Study (NCT05294419) evaluated participants undergoing primary care health checks. Both QRISK2 and CVD IRT scores were returned to the healthcare providers (HCPs), who then communicated the results to participants. The primary outcome of the study was feasibility of CVD IRT implementation. Secondary outcomes included changes in CVD risk (QRISK2 vs. CVD IRT) and impact of the CVD IRT on clinical decision-making. A total of 832 eligible participants (median age 55 years, 62% females, 97.5% White ethnicity) were enrolled across 12 UK primary care practices. Cardiovascular disease IRT scores were obtained on 100% of the blood samples. Healthcare providers stated that the CVD IRT could be incorporated into routine primary care in a straightforward manner in 90.7% of reports. Participants stated they were ‘likely’ or ‘very likely’ to recommend the use of this test to their family or friends in 86.9% of reports. Participants stated that the test was personally useful (98.8%) and that the results were easy to understand (94.6%). When CVD IRT exceeded QRISK2, HCPs planned changes in management for 108/388 (27.8%) of participants and 47% (62/132) of participants with absolute risk score changes of >2%. Conclusion Amongst HCPs and participants who agreed to the trial of genetic data for refinement of clinical risk prediction in primary care, we observed that CVD IRT implementation was feasible and well accepted. The CVD IRT results were associated with planned changes in prevention strategies.

Funder

Genomics PLC

NHS

Publisher

Oxford University Press (OUP)

Subject

Cardiology and Cardiovascular Medicine,Epidemiology

Reference31 articles.

1. Heart disease and stroke statistics—2022 update: a report from the American Heart Association;Tsao;Circulation,2022

2. An independent and external validation of QRISK2 cardiovascular disease risk score: a prospective open cohort study;Collins;BMJ,2010

3. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines;Arnett;Circulation,2019

4. Genes, the heart and destiny;White;N Engl J Med,1957

5. Polygenic and clinical risk scores and their impact on age at onset and prediction of cardiometabolic diseases and common cancers;Mars;Nat Med,2020

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3